©2024 Stanford Medicine
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Not Recruiting
Trial ID: NCT04077372
Purpose
The purpose of the study is to determine whether standardized implementation of a scripted
template for discussing important issues that arise near the end of life improves the care of
those who have advanced cancer.
Official Title
A Randomized, Controlled Trial Examining the Use of The "Serious Illness Conversation Guide" (SICG) in Patients With Advanced Gastro-Intestinal Cancers
Stanford Investigator(s)
Tyler Johnson
Clinical Associate Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
- Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX
and FOLFIRI.
- Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF
V600E mutation may be enrolled regardless of prior chemotherapy.
- Exception: Patients whose tumors are MSI-H must have experience progression through
immunotherapy in addition to the therapies mentioned above.
- Patients with metastatic pancreatic adenocarcinoma.
- Patients with metastatic gastric or esophageal cancer whose tumor has progressed
through first-line chemotherapy of any type.
- Patients with metastatic cholangiocarcinoma whose tumor has progressed through
first-line chemotherapy of any type.
- Patients with metastatic hepatocellular carcinoma whose tumor has progressed through
PD1 blockade.
- Patients with metastatic high-grade neuroendocrine tumor.
- A patient with a metastatic GIST that has progressed through first-line tyrosine
kinase inhibitor.
- Expected life expectancy of at least one month
Exclusion Criteria:
- Any patient not meeting the above criteria
- Non-English speaking patients
Intervention(s):
behavioral: Serious Illness Conversation Guide (SICG)
behavioral: Quality of Life (QOL) survey
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Daniel Holguin
6507363379